This study is currently not recruiting participants.

A Phase 3 Multicenter Randomized Double-blind Active ComparatorcontrolledStudy to Evaluate the Safety Tolerability and Immunogenicity of V114 Followedby Administration of PNEUMOVAX23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease

Not Recruiting
99 years or below
All
Phase 3
25 participants needed
1 Location

Brief description of study

Phase 3, Multicenter, Randomized, Double-blind, Active Comparatorcontrolled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 829946

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.